Ustekinumab is used to treat plaque psoriasis in adults and children who are at least 6 years old. Ustekinumab is also used to treat psoriatic arthritis in adults, and is sometimes given with another medicine called methotrexate. Ustekinumab is also used in adults to treat moderately to severely active Crohn's disease or ulcerative colitis Ustekinumab is a new medication, so there is very limited information on its safety for women who are pregnant or breastfeeding. If you are planning a pregnancy or become pregnant whilst taking ustekinumab, you must let your specialist know. They will discus Ustekinumab. Ustekinumab (Stelara) developed by Janssen-Cilag, Germany is a human monoclonal antibody that binds to the shared p40 protein subunit of the human interleukins 12 and 23, thereby preventing interaction with their cell surface IL-12-Rβ1 receptor

Ustekinumab is a human immunoglobulin (Ig) G1 kappa monoclonal antibody directed against interleukin (IL)-12 and IL-23, which are cytokines that are involved in immune and inflammatory responses. 2 It was generated via recombinant human IL-12 immunization of human Ig (hu-Ig) transgenic mice. 2 It is a targeted biologic disease-modifying anti. يعد دواء يوستيكينوماب (Ustekinumab)، الذي يباع تحت اسم دواء ستيلارا، علاج بالأجسام المضادة، حيث يستخدم لإدارة الحالات الالتهابية مثل صدفية الطبقات والتهاب المفاصل الصدفي ومرض كرون والتهاب القولون التقرحي، فما هي موانع.

Ustekinumab Uses, Side Effects & Warnings - Drugs

  1. Ustekinumab attaches to 2 messenger molecules in the immune system called interleukin 12 and interleukin 23. Both are involved in inflammation and other processes that are important in psoriasis, psoriatic arthritis, Crohn's disease and ulcerative colitis. By blocking their activity, ustekinumab reduces the activity of the immun
  2. Description: Ustekinumab is a recombinant human monoclonal antibody.It binds to and inhibits interleukins (IL)-12 and IL-23 cytokines which are involved in inflammatory and immune responses such as natural killer (NK) cell activation and CD4+ T-cell activation and differentiation
  3. STELARA ® (ustekinumab) is a prescription medicine that affects your immune system. STELARA ® can increase your chance of having serious side effects including

Samsung Bioepis launches a potential pivotal trial for its SB17 ustekinumab biosimilar candidate. Just days after Bio-Thera announced initiation of a phase 3 study of patients receiving a candidate ustekinumab biosimilar, Samsung Bioepis said that it, too, has begun a phase 3 clinical trial for its. Ustekinumab is a fully human IgG1κ monoclonal antibody that binds with specificity to the shared p40 protein subunit of human cytokines interleukin (IL)-12 and IL-23. Ustekinumab inhibits the bioactivity of human IL-12 and IL-23 by preventing p40 from binding to the IL-12Rβ1 receptor protein expressed on the surface of immune cells Ustekinumab is supplied as a sterile solution in a single-use pre-filled syringe containing 45 mg ustekinumab in 0.5 ml and should be injected under the skin of the stomach, thighs or upper outer arms Ustekinumab (Stelara, CNTO 1275) is an anti-IL-12/IL-23 IgG1κ human monoclonal antibody used to treat psoriasis. MW=145.6 kDa. In vitro: The addition of Ustekinumab (UST) significantly inhibits T follicular helper (TFH) cell differentiation in vitro. In viv Ustekinumab is an injectable biologic drug that suppresses the immune system and is used for the treatment of psoriasis.It is an antibody that binds to interleukin (IL)-12 and IL-23, two chemicals produced by cells in the body that stimulate immune reactions

Ustekinumab is a synthetic (man-made) antibody that is created inside living cells. Ustekinumab is an anti-interleukin biologic medicine. It targets two proteins in the body called interleukin-12 (IL-12) and interleukin-23 (IL-23). IL-12 and IL-23 are naturally produced in the body to help fight infections by temporarily causing inflammation Ustekinumab puede aumentar el riesgo de infecciones y reactivar las infecciones latentes. En los ensayos clínicos se han observado infecciones bacterianas, fúngicas y víricas graves en pacientes tratados conSTELARA (ver sección4.8). Se actuará con precaución cuando se valore la administración de STELARA a pacientes con algun Evaluation of loss of response to therapy. Quantification of ustekinumab in human serum. Trough level quantitation for evaluation of patients treated with ustekinumab. Detection of antibodies to ustekinumab in human serum. A profile is a group of laboratory tests that are ordered and performed together under a single Mayo Test ID Ustekinumab (trade name Stelara) is a type of biological therapy. It works by binding to two specific proteins on cells, which in turn interferes with the function of a group of white blood cells called T cells contains 130 mg of ustekinumab. 2. Withdraw, and then discard a volume of the 0.9% Sodium Chloride Injection,USP from the 250 mL infusion bag equal to the volume of STELARA ® to be added (discard 26 mL sodium chloride for each vial of STELARA ® needed, for 2 vials- discard 52 mL, for 3 vials- discard 78 mL, 4 vials- discard 104 mL). 3

Ustekinumab (brand name STELARA™) is a biological treatment used to treat moderate to severe psoriasis. It is a human monoclonal antibody that antagonises interleukin -12 (IL-12) and IL-23. Good to excellent responses are seen in more than two-thirds of patients with chronic plaque psoriasis treated with ustekinumab Ustekinumab is a human IgG1к monoclonal antibody that blocks the biological activity of interleukin 12 and interleukin 23 by acting on T cells, natural killer cells and receptors on antigen presenting cells . Interleukin 12 and interleukin 23 are involved in the differentiation of Th1 and Th17 cells Results showed at the end of 52 weeks, 58% of patients had achieved steroid-free remission and 65% had achieved clinical remission. At week 52, of the 39 patients who continued on ustekinumab, 62% of patients required dosing every 4 to 7 weeks to maintain remission (Dayan 2019) Ustekinumab (Stelara®) for the treatment of adult patients with moderately to severely active Crohn's disease who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumour necrosis factor-alpha antagonist or have medical contraindications to such therapies (July 2017) Recommended Background: Safe and effective therapies are needed for pediatric patients with psoriasis. Objective: The purpose of this study was to evaluate ustekinumab in patients age 12 to 17 years who had moderate-to-severe psoriasis. Methods: Patients (n = 110) were randomly assigned to ustekinumab standard dosing (SD; 0.75 mg/kg [≤60 kg], 45 mg [>60-≤100 kg], and 90 mg [>100 kg]) or half-standard.

FDA Approves Stelara® (Ustekinumab) For Treatment Of

Ustekinumab - an overview ScienceDirect Topic

The median follow-up on ustekinumab therapy was 10.7 months (range, 1.4-67.3). Twelve patients (17.1%) withdrew the treatment after a median of 7.4 months (range, 0.9-23.8). The cumulative probability of maintaining ustekinumab treatment was 97.1% at 6 months and 77.1% at 12 months Ustekinumab injection is also used to treat Crohn's disease (a condition in which the body attacks the lining of the digestive tract, causing pain, diarrhea, weight loss, and fever) in adults. Ustekinumab injection is also used to treat ulcerative colitis (a condition which causes swelling and sores in the lining of the colon [large intestine. Ustekinumab is used to treat plaque psoriasis, a certain type of arthritis (psoriatic arthritis), or a certain bowel condition (Crohn's disease). It works by blocking certain natural proteins in your body (interleukin-12 and interleukin-23) that cause inflammation (swelling) in these conditions. Ustekinumab does not cure thes Pharmacokinetics and Exposure Response Relationships of Ustekinumab in Patients With Crohn's Disease Omoniyi J. Adedokun,1 Zhenhua Xu,1 Christopher Gasink,2 Douglas Jacobstein,1 Philippe Szapary,1 Jewel Johanns,1 Long-Long Gao,2 Hugh M. Davis,1 Stephen B. Hanauer,3 Brian G. Feagan,4 Subrata Ghosh,5 and William J. Sandborn6 1Janssen Research & Development, LLC., Spring House, Pennsylvania. Following a single IV dose of ~6 mg/kg or a 130-mg fixed dose of STELARA, median serum ustekinumab concentrations were dose-proportional (median peak concentrations 1 hour after IV induction at week 0 were 127.0 µg/mL for the ~6 mg/kg group compared to 43.2 µg/mL for the 130 mg group). During maintenance therapy with STELARA 90 mg SC, steady.

Ustekinumab: Uses, Interactions, Mechanism of Action

Ustekinumab does not cure these diseases, but helps to lessen symptoms of the disease. It can help to decrease the amount of plaques in plaque psoriasis, decrease the number of swollen/painful joints in psoriatic arthritis, and decrease symptoms such as abdominal pain/cramping and diarrhea in Crohn's disease and ulcerative colitis STELARA ® is a prescription medicine used to treat adults 18 years and older with moderately to severely active Crohn's disease.. STELARA ® is a prescription medicine used to treat adults 18 years and older with moderately to severely active ulcerative colitis.. STELARA ® is a prescription medicine used to treat adults and children 6 years and older with moderate to severe psoriasis who.

Ustekinumab ist ein humaner monoklonaler Antikörper des Typs IgG1κ . Er bindet spezifisch an die p40-Protein-Untereinheit von IL-12 und IL-23 und verhindert deren Bindung an den Zielrezeptor . Dadurch wird die Überproliferation und Differenzierung zu TH1- und TH17- Zellen reduziert. Der gesamte Entzündungsprozess wird abgeschwächt

دواء يوستيكينوماب (Ustekinumab)؛ دواعي استعمال يوستيكينوما

Hi Guys, I hope you enjoyed this video! Please give it a thumbs up if you did and subscribe if you would like to see more from me! Other Popular Videos:How t.. Ustekinumab clearance increased with decreasing serum albumin and increasing bodyweight. fCal decreased with increasing ustekinumab exposure. The probability of endoscopic response at w24 increased from 10.0% to 17.9% with fCal at w8 decreasing from 1800 μg/g to 694 μg/g (EC 50)

Ustekinumab: Indication, Dosage, Side Effect, Precaution

Ustekinumab (also known as Stelara) is approved as a treatment for the skin condition of moderate to severe plaque-type psoriasis, but this study will examine if ustekinumab can provide benefit in Crohn's disease and also assess for any risks or side effects. Both the positive and negative outcomes of IV placebo versus two different doses of IV. Ustekinumab is a human monoclonal antibody to interleukin (IL) 12/23p40, first approved to treat patients with moderate to severe psoriasis in 2009. 1-3 Ustekinumab has also become a well-established therapy in Crohn's disease (CD), after initial approval in 2016, 4-6 and received initial approval for ulcerative colitis (UC) in September. As 'raw material' for the production of drug aliquots, Evidentic sources RMP from the European (EU) market. As a licensed pharmaceutical wholesaler, Evidentic is committed to Good Distribution Practice (GDP) compliance with respect to the procurement, storage and shipment of RMP Ustekinumab, sold under the brand name Stelara, is a monoclonal antibody medication developed by Janssen Pharmaceuticals, for the treatment of Crohn's disease, ulcerative colitis, plaque psoriasis and psoriatic arthritis. It targets both IL-12 and IL-23. . It is approved to treat Crohn's disease in the United States, Israel, Australia, and the European Union (EU), and ulcerative colitis in the.

Crohn's Disease, PsO & PsA Treatment STELARA® (ustekinumab

L'ustékinumab est un anticorps monoclonal dirigé contre les interleukines 12 et 23 (par l'intermédiaire d'une sous-unité commune), développé comme médicament. Efficacité. Avec une injection sous-cutanée tous les trois mois, il est efficace dans le traitement des psoriasis modérés à sévères [1], même si un rythme d'injection plus élevé est parfois nécessaire [2] Stelara (ustekinumab) treatment costs. The cost for a monthly or yearly treatment of Stelara (ustekinumab) depends on your prescription requirements which includes the dosage in g/mg/ml/etc and medicine type (Single-dose prefilled syringe). The price of the medicines you see on sale is the cost set by the manufacturer

Samsung Bioepis Initiates Phase 3 Ustekinumab Tria

Ustekinumab, a monoclonal antibody to the p40 subunit of interleukin-12 and interleukin-23, was evaluated as an intravenous induction therapy in two populations with moderately to severely active. In UC, the next wave of therapies is based on direct interleukin inhibition. Given the success of IL-12 and IL-23 blockade in psoriasis (Lancet 2008;371:1665-1674), and the emergence of ustekinumab (UST) as a promising new strategy for the treatment of Crohn's disease (CD), it has been assessed for the treatment of UC

Stelara psoriasis drug injection - Stock Image - C019/7438

Ustekinumab is a human monoclonal antibody. It is directed against interleukin 12and interleukin 23, naturally occurring proteins that regulate the immune system and immune-mediated inflammatory disorders Ustekinumab is a fully human monoclonal antibody targeting the common p40 subunit of IL‐12 and IL‐23. Through the inhibition of IL‐23, ustekinumab limits the differentiation of naïve T cells to T H 17 cells. While clinical efficacy was well documented in the CERTIFI and UNITI trials, a more rapid clinical response at induction was. Since ustekinumab reduces inflammation by acting on your immune system, there is the concern ustekinumab might affect the immune system in an infant who was exposed during pregnancy. Most vaccines given in the first 6 months of life are noninfectious and can be given to a baby even if ustekinumab is present in their blood

STELARA 45 mg solution for injection (vials) - Summary of

Ustekinumab is a prescription medication used to treat moderate to severe psoriasis, Crohn's disease, and active psoriatic arthritis. It is given as an infusion into a vein (IV) or as an injection under the skin. Ustekinumab is sold under the brand name Stelara® STELARA ® (ustekinumab), a human IL-12 and IL-23 antagonist, is approved in the United States for the treatment of: 1) adults and children 12 years and older with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy; 2) adult patients (18 years or older) with active psoriatic arthritis, used alone or in.

Ustekinumab - British Association of Dermatologist

  1. Ustekinumab is an immunosuppressant used to treat Crohn's disease, ulcerative colitis, plaque psoriasis, and psoriatic arthritis. The first 3 sentinel groups have received treatment and have reported no significant adverse events (AEs) to date, so the study has been extended to all 3 clinical sites
  2. Ustekinumab has demonstrated short- and mid-term efficacy in AS, 23 and we have previously reported that ustekinumab was effective in patients with peripheral SpA. 24 Conversely, the effect of ustekinumab on axial SpA failed to significantly differ from that observed in the placebo group after 24 weeks of therapy. 16 Although evaluated using.
  3. Head-to-head trial compares ustekinumab with adalimumab in Crohn's. For biologic-naive adults with moderate to severe Crohn's disease, treatment with adalimumab or ustekinumab leads to similar outcomes, according to results of the head-to-head SEAVUE trial. When lead author Bruce E. Sands, MD, of Icahn School of Medicine at Mount Sinai, New.
  4. Global Ustekinumab Market report provides sales, revenue share, pricing model, and gross margins of the leading players. Updates on market concentration ratio, mergers & acquisitions.
  5. Ustekinumab is a fully human IgG1κ monoclonal antibody to interleukin (IL)-12/23 produced using recombinant DNA technology. Ustekinumab is licensed for the management of plaque psoriasis, psoriatic arthritis, Crohn's disease and ulcerative colitis
  6. Ustekinumab 90 mg per 1 ml; 1: pre-filled disposable injection (POM) £2147.00 (Hospital only) — — Solution for infusion All products. Cautionary and advisory labels. Label 10.
  7. La inyección de ustekinumab se utiliza para tratar psoriasis en placas de moderada a grave (una enfermedad de la piel en la cual se forman parches rojos y escamosos en algunas áreas del cuerpo) en adultos y niños de 6 años y mayores que pueden beneficiarse de medicamentos o fototerapia (un tratamiento que implica exponer la piel a la luz ultravioleta)

Ustekinumab level Test Code SAUKL Specimen Type Serum - GEL Minimum Volume 2mL Preferred Volume 7mL Comments LAB NOTES Store and transport serum at 4oC to referral laboratory Assay Performed Sullivan Nicolaides Pathology 24 Hurworth Street BOWEN HILLS, QLD, 4006 Assay Frequency Performed fortnightly Cost $109.00 MBS item number 66812 - Partial. Ustekinumab distributes into milk in monkeys, and maternal IgG distributes into human milk. Systemic exposure to ustekinumab in breast-fed infants is expected to be low since the drug is a large molecule and is degraded in the GI tract. Any effects of local exposure to ustekinumab in the GI tract are unknown Antibodies- Ustekinumab of ATU, consider optimizing to-ustekinumab detected quantification therapy by increasing the can contribute to faster 1.0 mcg/mL dose or shortening the clearance of ustekinumab administration intervals, and treatment failure. or by adding an immuno- Clinical evaluation is modulator to the recommended Ustekinumab doses every 12 weeks and every 8 weeks generally performed similarly during the LTE for most clinical measures. The every-8-weeks dose appeared to have numerically greater percentages of patients in clinical remission than the every-12-weeks dose, particularly in the last year of the LTE among TNF antagonist-naïve patients

Ustekinumab (anti-IL-12/IL-23) Interleukins inhibitor

  1. Ustekinumab ( Stelara, Janssen) appears superior to vedolizumab ( Entyvio, Takeda) on multiple measures of response and remission among patients with Crohn's disease who failed at least one anti.
  2. Stelara (ustekinumab) is an expensive drug used to treat plaque psoriasis, psoriatic arthritis and ulcerative colitis.This medicine is also used to treat Crohn's disease.It is not a cure. This drug is more popular than comparable drugs
  3. Ustekinumab, which is among the highest selling pharmaceutical products in the world, had worldwide sales of $7.7 bn in 2020. AVT04 is the second proposed biosimilar product from Alvotech entering.
  4. Ustékinumab : Mécanisme d'action. L'ustékinumab est un anticorps monoclonal IgG1kappa entièrement humain qui se lie avec une forte affinité et spécificité à la sous-unité protéique p40 des cytokines humaines IL-12 et IL-23. L'ustékinumab inhibe l'activité de l'IL-12 et de l'IL-23 humaines en empêchant ces cytokines de se lier à.
  5. Cosa contiene Stelara. Il principio attivo è ustekinumab. Ogni flaconcino contiene 45 mg di ustekinumab in 0,5 ml. Gli eccipienti sono: L-istidina, L-istidina monocloridrato monoidrato, polisorbato 80, saccarosio, acqua per preparazioni iniettabili. Descrizione dell'aspetto di Stelara e contenuto della confezione
  6. Ustekinumab inibisce l'attività biologica di IL-12 e di IL-23 umane, impedendo il legame di p40 con la proteina recettoriale IL-12R 1 espressa sulla superficie delle cellule immunitarie. Ustekinumab non può legarsi a IL-12 o a IL-23 che sono già legate ai recettori IL-12R 1 presenti sulla superficie cellulare

ustekinumab (Stelara): Psoriasis Drug Side Effects & Dosag

  1. In the ustekinumab group, response rates across other disease measures were also maintained through week 48. Among patients in the placebo group who crossed over to ustekinumab treatment (n = 33), increased response rates across efficacy measures were noted. Among all ustekinumab-treated patients, 81.7% had ≥1 adverse event (AE), and 15.1%.
  2. Ustekinumab is a human 1gG1 K monoclonal antibody that inhibits the biologic activity of cytokines interleukin-12 and interleukin-23 through the common p40 subunit.The treatment also has shown efficacy in treating chronic plaque psoriasis and active psoriatic arthritis
  3. Ustekinumab is available as Stelara (Janssen Biotech, Inc.). Ustekinumab (UST) is a human interleukin-12 and -23 antagonist. IL-12 and IL-23 are naturally occurring cytokines that are involved in inflammatory and immune responses, such as natural killer cell activation and CD4+ T-cell differentiation and activation
  4. Stelara (ustekinumab) is an expensive drug used to treat plaque psoriasis, psoriatic arthritis and ulcerative colitis. This medicine is also used to treat Crohn's disease. It is not a cure. This drug is more popular than comparable drugs. There are currently no generic alternatives to Stelara
  5. Objective Interleukin (IL)-12 and IL-23 have been implicated in the pathogenesis of rheumatoid arthritis (RA). The safety and efficacy of ustekinumab, a human monoclonal anti-IL-12/23 p40 antibody, and guselkumab, a human monoclonal anti-IL-23 antibody, were evaluated in adults with active RA despite methotrexate (MTX) therapy. Methods Patients were randomly assigned (1:1:1:1:1) to receive.
  6. INTRODUCTION. Ustekinumab is a human monoclonal antibody to interleukin (IL) 12/23p40, first approved to treat patients with moderate to severe psoriasis in 2009. 1-3 Ustekinumab has also become a well-established therapy in Crohn's disease (CD), after initial approval in 2016, 4-6 and received initial approval for ulcerative colitis (UC) in September 2019
Rapid Dactylitis Resolution in a Patient With Psoriatic

Ustekinumab Crohn's & Colitis U

  1. Ustekinumab drug level: <0.1 μg/mL. • Result ≥0.1 μg/mL indicates detection of ustekinumab. • In the presence of anti-ustekinumab antibodies, the ustekinumab drug level reflects the free, antibody-unbound fraction of ustekinumab in serum. Anti-ustekinumab antibody: <40 ng/mL
  2. ed by X-ray crystallography at 3.0 Å resolution
  3. Ustekinumab onderdrukt de lichaamsafweer en remt ontstekingen. Bij psoriasis (schilferende huidaandoening), bij artritis psoriatica, bij de ziekte van Crohn, bij colitis ulcerosa en soms bij sarcoïdose (ziekte van Besnier Boeck). Bij deze ziekten valt de lichaamsafweer de eigen cellen aan, waardoor deze ontstoken raken
  4. 5. Papp KA, Griffiths CE, Gordon K, et al. Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up. Br J Dermatol. 2013 Apr;168(4):844-54. 6. Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1
  5. o acids and has an estimated molecular mass that ranges from 148,079 to 149,690 Daltons. STELARA ® (ustekinumab) injection is a sterile, preservative-free, colorless to light yellow solution and may contain a few small translucent or white particles with pH of 5.7- 6.3
  6. The phase 3 (UNIFI) trial of ustekinumab (anti-interleukin 12/23) demonstrated efficacy even after prior biologic failure in adult ulcerative colitis (UC), but paediatric data are lacking. Aim. To prospectively monitor efficacy and serum concentrations of ustekinumab given to children with UC refractory to other biologics. Method
  7. Objective To evaluate ustekinumab efficacy and safety in psoriatic arthritis (PsA) patients with peripheral arthritis and physician-reported spondylitis (termed the 'spondylitis subset'). Methods Adults with active PsA (PSUMMIT-1/PSUMMIT-2, n=615/312) were randomised to ustekinumab 45 mg, 90 mg or placebo at week 0/week 4/q12 week. At week 16, patients with <5% improvement in tender and.

Video: USTEK - Overview: Ustekinumab Quantitation with Antibodies

Ustekinumab Side-effects, uses, time to wor

Thus, although ustekinumab was designed to target IL-12, it also modulates IL-23, a cytokine important to the development and/or maintenance of TH17 cells. Clinical observations established that. Ustekinumab is used to treat plaque psoriasis in adults and children who are at least 12 years old. Ustekinumab is also used to treat psoriatic arthritis in adults, and is sometimes given with another medicine called methotrexate.. Ustekinumab is also used in adults to treat moderately to severely active Crohn's disease or ulcerative colitis.. Ustekinumab may also be used for purposes not. Ustekinumab was associated with improved clinical response and remission versus placebo during induction and maintenance treatment in patients with moderately to severely active Crohn's disease who had failed to respond to or not tolerated conventional therapy or TNFα antagonists. This SMC advice takes account of the benefits of a Patient.

Ustekinumab for psoriasis DermNet N

Ustekinumab showed larger treatment effects compared to etanercept in terms of PASI-75 responder rates over a 12-week period, with NNTs of 9.3 and 5.9 for the 45-mg and 90-mg doses, respectively. Ustekinumab was superior to etanercept in terms of PASI-75 improvement, PASI-90 improvement, and PGA outcome measures at week 12 Formycon and Bioeq announce Launch of Phase III Study of FYB202, a Biosimilar Candidate for Stelara (R)* (Ustekinumab) The active ingredient ustekinumab is a human monoclonal antibody that targets the cytokines interleukin-12 and interleukin-23. Since 2009, Stelara (R) has been used to treat various severe in.. View article

Stelara Injection (Ustekinumab) Drug InformationReversible Posterior Leukoencephalopathy Syndrome in aPsoriasis – Dr[Full text] Hidradenitis Suppurativa as a Paradoxical SideBiologics and Psoriasis: the Beat Goes On | AAD Highlights

Ustekinumab concentration was measured in 90% of patients still on drug at 52 weeks. Ustekinumab is a first-in-class therapeutic human IgG1 kappa monoclonal antibody (mAb) that binds to interleukins (IL)-12 and IL-23, cytokines that modulate lymphocyte function, including T-helper (Th)-1 and Th17 cell subsets Ustekinumab D09214 Ustekinumab (USAN/INN) Therapeutic category of drugs in Japan [BR:br08301] 3 Agents affecting metabolism 39 Other agents affecting metabolism 399 Miscellaneous 3999 Others D09214 Ustekinumab (USAN/INN); Ustekinumab (genetical recombination) (JAN) Target-based classification of drugs [BR:br08310] Cytokines and receptors Cytokine Ustekinumab (Handelsname Stelara ®; Hersteller Janssen-Cilag) ist ein Arzneistoff, der in der Behandlung der Psoriasis eingesetzt wird. Ustekinumab ist ein humaner monoklonaler Antikörper gegen die Zytokine Interleukin-12 (IL-12) und Interleukin-23 (IL-23) und seit Januar 2009 zugelassen